Abstract

The overall objective of the program project is to develop HIV- vaccines suitable for human use. Once optimal HIV-1 immunogens, adjuvants, carriers, and immunization protocols have been determined in preliminary studies in rhesus monkeys, the specific aims of this research project are to assess their efficacy in chimpanzees through their capability to induce humoral and cell-mediated immune responses in these animals and to prevent infection following a live HIV-1 challenge. Chimpanzees will be immunized at 0, 1, and 6 months. If they respond with good humoral and cell-mediated immune responses as assayed by enzyme linked immunoassay, neutralization assay, antibody dependent cellular cytotoxicity, Western blot, radioimmunoprecipitation, lymphocyte blastogenesis, and cytotoxic T lymphocytes, they will be challenged i.v. 2 weeks later with 100 TCID50 of HIV-1. Besides following their immune responsiveness, their status will be assessed by HIV-1 isolation attempts from their lymphocytes and sera through reverse transcriptase and p24 antigen detection assays.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project--Cooperative Agreements (U01)
Project #
3U01AI026471-05S1
Application #
3769110
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
5
Fiscal Year
1993
Total Cost
Indirect Cost

  Institution

Name
University of California Davis
Department
Type
DUNS #
094878337
City
Davis
State
CA
Country
United States
Zip Code
95618

  Publications

Serrano, D; Becker, K; Cunningham-Rundles, C et al. (2000) Characterization of the T cell receptor repertoire in patients with common variable immunodeficiency: oligoclonal expansion of CD8(+) T cells. Clin Immunol 97:248-58
Gardner, M; Rosenthal, A; Jennings, M et al. (1995) Passive immunization of rhesus macaques against SIV infection and disease. AIDS Res Hum Retroviruses 11:843-54
Dumitrescu, O; Kalish, M L; Kliks, S C et al. (1994) Characterization of human immunodeficiency virus type 1 isolates from children in Romania: identification of a new envelope subtype. J Infect Dis 169:281-8
Barnett, S W; Murthy, K K; Herndier, B G et al. (1994) An AIDS-like condition induced in baboons by HIV-2. Science 266:642-6
Gardner, M B; Rosenthal, A; Jennings, M et al. (1994) Passive immunization of macaques against SIV infection. J Med Primatol 23:164-74
Giavedoni, L D; Planelles, V; Haigwood, N L et al. (1993) Immune response of rhesus macaques to recombinant simian immunodeficiency virus gp130 does not protect from challenge infection. J Virol 67:577-83
Montefiori, D C; Graham, B S; Kliks, S et al. (1992) Serum antibodies to HIV-1 in recombinant vaccinia virus recipients boosted with purified recombinant gp160. NIAID AIDS Vaccine Clinical Trials Network. J Clin Immunol 12:429-39
Popov, J; McGraw, T; Hofmann, B et al. (1992) Acute lymphoid changes and ongoing immune activation in SIV infection. J Acquir Immune Defic Syndr 5:391-9
Giavedoni, L D; Jones, L; Gardner, M B et al. (1992) Vaccinia virus recombinants expressing chimeric proteins of human immunodeficiency virus and gamma interferon are attenuated for nude mice. Proc Natl Acad Sci U S A 89:3409-13
Planelles, V; Haigwood, N L; Marthas, M L et al. (1991) Functional and immunological characterization of SIV envelope glycoprotein produced in genetically engineered mammalian cells. AIDS Res Hum Retroviruses 7:889-98

Showing the most recent 10 out of 23 publications